SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QDEL - Quidel more quick diagnosis
QDEL 21.60+2.9%11:04 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: steve dietrich who wrote (885)6/17/1997 9:37:00 PM
From: Dennis C   of 1693
 
This year's expense will be lic. fee + sale% = 1.9 mil. Does anyone have idea about typical lic. fee? It is not hard to figure out the royalty number (sale%) if you know lic fee.

In the future QDEL will also recieve something related to the "Q-labled technology" from the sucker BD. Hope this number can offset the yoyalty payment to BD.

Here is the Reuter's version:

Quidel says settlement may cause expense

SAN DIEGO, June 17 (Reuter) - Quidel Corp said Tuesday it has settled the lawsuit filed in April 1997 by Becton Dickinson and Co,
and estimates the terms of the settlement could result in an annual expense of about $1.9 million.

The lawsuit alleged Quidel's strep and chlamydia products and certain of its pregnancy and ovulation products infringe two Becton
patents.

Quidel said under the settlement agreement, it received a license from Becton under both patents in exchange for a cash license fee,
and agreed to pay a royalty on net sales of the products beginning April 1.

Quidel said it also provided Becton a license to the its Q-Label technology with a royalty payable on future sales.

Quidel said it estimates the annual amortization of the license fee and the royalty payments, based on current product sales, could
result in an annual expense of $1.9 million.

Quidel said it believes it has opportunities to mitigate the impact of this additional expense through sales growth and improved margins
from favorable product mix.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News